Rubidium-82 generator yield and efficiency for PET perfusion imaging: Comparison of two clinical systems

Ali Ahmadi, MD, PhD,a Ran Klein, PhD,b Howard C. Lewin, MD,c Rob S. B. Beanlands, MD,a and Robert A. deKemp, PhDa

a Division of Cardiology, University of Ottawa Heart Institute, National Cardiac PET Centre, Ottawa, ON, Canada
b Division of Nuclear Medicine, The Ottawa Hospital, Ottawa, ON, Canada
c Cardiac Imaging Nuclear Associates, Los Angeles, CA

Received Feb 13, 2020; accepted Apr 18, 2020
doi:10.1007/s12350-020-02200-6

Introduction. Strontium-82/Rubidium-82 (82Sr/82Rb) generators are used widely for positron emission tomography (PET) imaging of myocardial perfusion. In this study, the 82Rb isotope yield and production efficiency of two FDA-approved 82Sr/82Rb generators were compared.

Methods. N = 515 sequential daily quality assurance (QA) reports from 9 CardioGen-82® and 9 RUBY-FILL® generators were reviewed over a period of 2 years. A series of test elutions was performed at different flow-rates on the RUBY-FILL® system to determine an empirical correction-factor used to convert CardioGen-82® daily QA values of 82Rb activity (dose-calibrator ‘maximum’ of 50 mL elution at 50 mL·min⁻¹) to RUBY-FILL® equivalent values (integrated ‘total’ of 35 mL elution at 20 mL·min⁻¹). The generator yield (82Rb) and production efficiency (82Rb yield/82Sr parent activity) were measured and compared after this conversion to a common scale.

Results. At the start of clinical use, the system reported 82Rb activity from daily QA was lower for CardioGen-82® vs RUBY-FILL® (2.3 ± 0.2 vs 3.0 ± 0.2 GBq, P < 0.001) despite having similar 82Sr activity. Dose-calibrator ‘maximum’ (CardioGen-82®) values were found to under-estimate the integrated ‘total’ (RUBY-FILL®) activity by ~ 24% at 50 mL·min⁻¹. When these data were used to convert the CardioGen-82 values to a common measurement scale (integrated total activity) the CardioGen-82® efficiency remained slightly lower than the RUBY-FILL® system on average (88 ± 4% vs 95 ± 4%, P < 0.001). The efficiency of 82Rb production improved for both systems over the respective periods of clinical use.

Conclusions. 82Rb generator yield was significantly under-estimated using the CardioGen-82® vs RUBY-FILL® daily QA procedure. When generator yield was expressed as the integrated total activity for both systems, the estimated 82Rb production efficiency of the CardioGen-82® system was ~ 7% lower than RUBY-FILL® over the full period of clinical use. (J Nucl Cardiol 2020;27:1728–38.)

Key Words: Myocardial perfusion imaging • positron emission tomography • rubidium-82 generator • daily quality assurance

Electronic supplementary material The online version of this article (https://doi.org/10.1007/s12350-020-02200-6) contains supplementary material, which is available to authorized users. The authors of this article have provided a PowerPoint file, available for download at SpringerLink, which summarises the contents of the paper and is free for re-use at meetings and presentations. Search for the article DOI on SpringerLink.com.

Reprint requests: Robert A. deKemp, PhD, Division of Cardiology, University of Ottawa Heart Institute, National Cardiac PET Centre, 40 Ruskin Street, Ottawa, ON K1Y 4W7, Canada; RAdKeKemp@ottawaheart.ca

1071-3581/$34.00
Copyright © 2020 The Author(s)
Rubidium-82 generator yield and efficiency for PET perfusion imaging

Ahmadi et al 1729

INTRODUCTION

Rubidium-82 (82Rb) is a widely used positron emission tomography (PET) tracer with a short half-life of ~75 seconds. Stress perfusion imaging with 82Rb is used widely in cardiac PET centers for the assessment of known or suspected coronary artery disease. The short half-life of 82Rb allows rapid assessment of known or suspected coronary artery disease.13,14 In this context, the aims of the current study were to assess the isotope production efficiency (82Rb yield/82Sr parent activity) of two FDA-approved 82Sr/82Rb generators during their clinical shelf-life and to characterize the effect of different daily quality assurance (QA) procedures on measured 82Rb activity.

See related editorial, pp. 1739–1742

METHODS

Quality Assurance Procedures

Sequential daily QA reports (N = 515) were reviewed from 9 CardioGen-82® (Bracco Diagnostics Inc., Monroe, NJ) and 9 RUBY-FILL® (Jubilant DraxImage, Kirkland, QC) generators used at Cardiac Imaging Nuclear Associates, Inc. (Los Angeles, CA) over a continuous period from January 2017 to May 2019. Parent 82Sr activity was calculated on a given date Sr(d) based on the radiopharmaceutical calibration certificate activity on the date of manufacturing Sr(D0) = 100 mCi (3.7 GBq), according to the known isotope decay, i.e.

\[ Sr(d) = Sr(D_0) \times e^{-A(d-D_0)} \]  

where \( A = \ln(2/25.35) \text{ days} \) is the decay constant of 82Sr. The initial calibration activity of 82Sr parent was confirmed as 100 mCi (3.7 GBq) for all generators on the date of manufacturing (D0).

The operation of both 82Sr/82Rb elution systems follow similar principles as described before, and illustrated in Figure 1. Briefly, a syringe pump (CardioGen-82®) or peristaltic pump (RUBY-FILL®) is used to elute normal physiologic saline (0.9% NaCl USP) through the generator column. A system of tubing delivers the radioactive 82Rb eluate either to a sterile patient intravenous (IV) injection line or to a waste container. The CardioGen-82® was designed for elution at a constant flow-rate of 50 mL.min⁻¹. The RUBY-FILL® elution system allows variable flow-rates from 15 to 30 mL.min⁻¹. It has an additional generator-bypass line used to flush 82Rb activity out of the patient line at the end of elution. The bypass line can also be used with feedback control to standardize the shape of the infused activity profile, providing the same ‘square-wave’ injection regardless of the age of the generator.

The daily 82Rb calibration and breakthrough testing procedures use preset constant values for both the RUBY-FILL® (35 mL at 20 mL.min⁻¹) and CardioGen-82® (50 mL at 50 mL.min⁻¹) generators. The RUBY-FILL® system reports the second-by-second integrated ‘total’ activity delivered during the daily calibration elution, as shown in Figure 2. The CardioGen-82® system does not report the integrated total 82Rb activity as part of the daily QA procedures, but rather as the dose-calibrator ‘maximum’ value recorded at the end of the breakthrough testing elution.

For both generators, the 82Rb activity \( A_f(t) \) is delivered to the outlet of the patient infusion line at an instantaneous output-rate (MBq/s) that varies as a function of elution time t, and elution flow-rate F. During daily calibration the RUBY-FILL® system
measures the delivered activity as the cumulative integrated ‘total’ of the $^{82}$Rb activity delivered over $T = 105$ seconds duration of a 35 mL elution at $F = 20$ mL-min$^{-1}$, i.e.

$$\text{Rb}_{\text{TOTAL}}(T) = \int_0^T A_{20}(t) \, dt$$ (2)

On the CardioGen-82$^\circledR$ system, the dose-calibrator maximum activity is measured in a collection vial at the end of the 50 mL elution at $F = 50$ mL-min$^{-1}$, i.e. $\text{Rb}_{\text{MAX}}(T = 60\text{seconds})$ performed as part of the daily breakthrough testing (Supplemental Figure S1). Beyond the 60-seconds time-point, $^{82}$Rb activity in the vial reaches a maximum value representing a steady-state balance between rubidium activity output from the generator and isotope decay, according to:

$$\text{Rb}_{\text{MAX}}(T) = \int_0^T A_{50}(t) e^{-\lambda(T-t)} \, dt$$ (3)

where $\lambda = \ln(2)/75.35$ seconds is the decay constant of $^{82}$Rb.$^5$

The respective values, i.e. CardioGen-82$^\circledR$ ‘maximum’ and RUBY-FILL$^\circledR$ ‘total’ are reported here as the measured daily QA activity. The $^{82}$Rb yield is reported for both systems as the integrated total activity delivered over the time-course of an elution into the daily QA vial (Table 1).

CardioGen-82$^\circledR$ Correction Factor

On the RUBY-FILL$^\circledR$ system, the $^{82}$Rb yield is equal to the ‘Dose Delivered’ value shown on the daily QA calibration elution report (Supplemental Figure S2). To enable accurate comparison of $^{82}$Rb yield between the two systems, a correction factor was determined to scale the CardioGen-82$^\circledR$ daily QA activity (dose-calibrator maximum values) to the integrated total values that would be expected using the RUBY-FILL$^\circledR$ calibration procedure.

The CardioGen-82$^\circledR$ system operates at a fixed elution flow-rate of 50 mL-min$^{-1}$, whereas RUBY-FILL$^\circledR$ can operate over a range of flow-rates from 15 to 30 mL-min$^{-1}$. Since there was no single elution flow-rate that could be used to compare both systems directly, a series of test elutions (60-seconds duration) was performed using the RUBY-FILL$^\circledR$ generator ($n = 6$ days each) to measure the dose-calibrator ‘maximum’ activities produced over the range of available flow-rates (15, 20, 25 and 30 mL-min$^{-1}$). These values were expressed relative to the true integrated total activity measured on each day and plotted as a function of the elution flow-rate. Because the changes with flow-rate did not appear to be linear, two non-linear regression (logarithmic and power function) models were used to fit these data and extrapolate the maximum/total activity ratio expected at 50 mL-min$^{-1}$. The inverse ratio was...
then used as a correction factor to scale the measured CardioGen-82® dose-calibrator maximum values to the equivalent integrated total activity values ($^{82}$Rb yield), as measured by the RUBY-FILL® system.

**Generator Performance**

For the RUBY-FILL® test elutions, percent error in the integrated total activity (actual/requested – 1) × 100% was determined as a function of the elution flow-rate. The actual elution flow-rates were also verified by dividing the volume of the eluate (mL) by the elution time (minutes) and plotting the elution flow-rate error (actual/requested – 1) × 100% as a function of the requested flow-rate. For both systems, the generator efficiency was reported as the ratio of $^{82}$Rb yield (integrated total activity) divided by the $^{82}$Sr parent

---

**Table 1.** Activity, yield and efficiency methods for each elution system

| Generator system | Daily QA reported $^{82}$Rb activity | Report $^{82}$Rb yield | Calculated efficiency |
|------------------|--------------------------------------|------------------------|-----------------------|
| RUBY-FILL®       | Integrated total from calibration/breakthrough elution | Integrated total from calibration/breakthrough elution | Integrated total $^{82}$Rb yield/$^{82}$Sr parent |
| CardioGen-82®    | Dose Cal maximum from daily QA breakthrough elution | Integrated total estimated from daily QA and RUBY-FILL test elutions (1.3 × Max) | Integrated total $^{82}$Rb yield/$^{82}$Sr parent |

---

**Figure 2.** Example $^{82}$Rb generator activity output profiles from a RUBY-FILL® test elution performed at 20 mL/min. $^{82}$Rb eluate activity (MBq/s, blue) as measured at the output of the patient infusion line over time. Total activity delivered to the patient or calibration vial (MBq, solid orange line) increases over-time according to the integrated area under the $^{82}$Rb eluate time–activity curve. Activity measured in a dose-calibrator vial (CardioGen-82®) increases initially over time, but then reaches a steady-state maximum value (MBq, dashed orange line) which is lower than the integrated total activity.

In the context of evaluating generator performance, the RUBY-FILL® and CardioGen-82® systems each provide specific methods to report activity, yield, and efficiency. The RUBY-FILL® system utilizes integrated total activity from calibration/breakthrough elution, while CardioGen-82® employs the maximum from daily QA breakthrough elution. These methods enable a comprehensive assessment of generator output efficiency and reliability.
activity available over the course of the generator shelf-life:

\[
\text{Efficiency} = \frac{^{82}\text{Rb yield}}{^{82}\text{Sr parent activity}} \times 100\%
\] (4)

**Statistical Analysis**

All values are presented as mean ± standard deviation. Correlations of continuous data were assessed using parametric bivariate analysis. Logarithmic and power function regression models were used for the calibration data extrapolation. Comparison of data between generators was performed with a two-way analysis of variance (ANOVA) assuming unequal variances, and statistical significance was considered using \( P < 0.05 \). Statistical testing was performed using Excel \(^\text{®}\) v2017 (Microsoft Corp, Redmond, WA).

**RESULTS**

**Daily QA Measurements**

\(^{82}\text{Rb QA activity values were measured for 240 days with the CardioGen-82® system and for 275 days with RUBY-FILL® (N = 515 total). The average duration of clinical use was 32% longer with the RUBY-FILL® vs CardioGen-82® systems (54 ± 1 vs 41 ± 2 days, \( P < 0.001 \)) as expected given the different generator expiration dates (60 vs 42 days) and elution volume limits (30 vs 17 L) listed in the respective package inserts.\(^5,11\) The measured daily QA activity values are shown as a function of generator age (day of use) for both systems in Figure 3. On the first day of clinical use, the QA activity measured on the RUBY-FILL® system was 32% higher vs CardioGen-82® (Table 2), however on the last day of use the activity was the same for both systems (≈ 800 MBq [22 mCi] on day 56 for RUBY-FILL® or day 42 for CardioGen-82®). When the \(^{82}\text{Rb QA activity was expressed as a percentage of the \(^{82}\text{Sr parent activity available on a given day, the average value for the CardioGen-82® generator was 67.3 ± 3.4% compared to 95.0 ± 3.8% for RUBY-FILL® (\( P < 0.001 \)) over the full period of clinical use.\)**

**CardioGen-82® Correction Factor**

The difference in daily QA activities was due, in part, to the different measurement techniques (dose-calibrator maximum vs integrated total activity), therefore the corresponding values for the CardioGen-82® system were derived using the result of the RUBY-FILL® test elutions. Typical \(^{82}\text{Rb time activity curves (TACs) for the test elutions performed at different flow-rates are shown in Supplemental Figure S3. As expected, the 20-mL-min\(^{-1}\) test elution and calibration curves were nearly identical during the common 60-second elution interval. Percent error in the actual delivered vs. requested activity was consistently below 0.2% over the full range of flow-rates (Supplemental Figure S4A) confirming accuracy of the RUBY-FILL® elution system over the full range of flow-rates.\(^6\) Error in the actual vs requested flow-rate was below 6% for all elutions (Supplemental Figure S4B) demonstrating accuracy of the RUBY-FILL® peristaltic pump over the range of elution flow-rates tested. There was a negative correlation of flow-rate error with increasing flow-rate\(^2\) (\( R^2 = 0.85 \)), without significant error at 20-25 mL-min\(^{-1}.\) At each flow-rate tested, the dose-calibrator maximum activity was very highly correlated with the integrated total (\( R^2 > 0.99 \)) as shown in Figure 4A. The maximum/total activity ratios (slope of the lines in Figure 4A) increased significantly as a function of flow-rate, as summarized in Table 3. At an extrapolated flow-rate of 50 mL-min\(^{-1}\), the dose-calibrator maximum/total activity ratio was estimated as 0.750 ± 0.007 and 0.772 ± 0.008 using the logarithmic and power function models, respectively (Figure 4B). Both the non-linear functions had higher \( R^2 (> 0.98) \) than a linear model fit to the data (\( R^2 = 0.96 \)). The average value (0.761 ± 0.008) was used to compute the CardioGen-82® correction-factor as 1/0.761 = 1.314 ± 0.013.

**Generator Yield and Efficiency**

When the CardioGen-82® dose-calibrator maximum \(^{82}\text{Rb} \) values were multiplied by the estimated correction-factor (1.314), the integrated total \(^{82}\text{Rb} \) yield on the first day of use (day 0) was 3.03 ± 0.21 GBq, very similar to the value of 3.04 ± 0.17 GBq measured on the RUBY-FILL® system (day 4) as shown in Table 2. The corresponding CardioGen-82® efficiency was estimated as 88.4 ± 4.4% (Figure 5) which was slightly lower than the RUBY-FILL® efficiency of 95.0 ± 3.8% measured over the full period of clinical use \( (P < 0.001) \).

**DISCUSSION**

\(^{82}\text{Rb} \) stress PET has become a routine method for myocardial perfusion imaging including the quantification of absolute myocardial blood flow (mL-min\(^{-1}\)-g\(^{-1}\)). The utility of \(^{82}\text{Rb} \) PET to diagnose coronary artery disease and to guide appropriate treatment for CAD patients has been well-established previously.\(^17\) The documented prognostic value of \(^{82}\text{Rb} \) PET perfusion
its low-radiation exposure to patients and medical staff, and the availability of approved on-site $^{82}$Sr/$^{82}$Rb generators plays a key role in the increasing use of this modality. The number of imaging centers using $^{82}$Rb PET has risen dramatically since the initial commercial approval (CardioGen-82®) and subsequent addition (RUBY-FILL®) of these $^{82}$Rb generator systems. With this increase in clinical capacity and diversity of generator systems, the need for standardized patient dosing is critical, as the net

Figure 3. $^{82}$Rb daily QA activity (solid green lines) measured on RUBY-FILL® (A) and CardioGen-82® (B) generator systems. Activity is shown in mCi (GBq/37) on the left axis, and as a percent of the $^{82}$Sr parent activity available on each day of use (solid red lines) on the right axis.
amount of injected activity ultimately determines the PET image quality and absorbed radiation dose to the patient.22

This study compared the $^{82}$Rb production efficiency of the two-generator systems available for cardiac PET perfusion imaging, and characterized the daily QA procedure effects on measured isotope yield. The main findings indicated: (1) $^{82}$Rb yield of the CardioGen-82® generator was under-estimated by ~24% using dose-calibrator maximum values for daily QA; (2) a correction-factor of ~1.3 may be used to convert CardioGen-82® daily QA values to equivalent integrated total $^{82}$Rb activity as measured by the RUBY-FILL® system; (3) $^{82}$Rb isotope yield and production efficiency were estimated to be ~7% higher for the RUBY-FILL® vs CardioGen-82® system, as measured over a clinical shelf-life that was ~30% longer.

A novel method was developed to bring the $^{82}$Rb isotope yield measured by two different generators to a common scale for accurate comparison. The CardioGen-82® elution protocol recommends the patient maximum volume to be set at 50 mL and the patient dose at 1480 MBq (40 mCi), with a range of 1110-2220 MBq (30-60 mCi).11,23 The RUBY-FILL® system is user-adjustable for dose (e.g. 10-30 MBq·kg$^{-1}$ [0.27-0.81 mCi·kg$^{-1}$] body weight) and flow-rate (15-30 mL·min$^{-1}$) or infusion time (10-120 seconds).9,24 The infused patient activity is also reported differently by the two systems. RUBY-FILL® reports only the integrated total activity for both daily QA and patient studies. The CardioGen-82® system reports the integrated ‘Patient Dose’ and the ‘End-of-Infusion’ activity values, which must be calibrated at the same activity used for patient elutions. Neither of these activity values appear to be accurate on the daily QA breakthrough elution reports, therefore, they should not be used as a measure of CardioGen-82® $^{82}$Rb isotope yield.

Both generator systems showed a small increase in $^{82}$Rb isotope production efficiency over time (Figure 5). The mechanism for this observed improvement is not completely understood but may be due to migration of $^{82}$Sr activity away from the column inlet, where it can be eluted from the column more completely. The difference in measured efficiency between vendors may be due to alternative chemical preparation/conditioning of the column resin and/or physical geometry/volume of exchanger in the generator columns, but these are proprietary data and difficult to confirm.

Three-dimensional (3D) PET systems are the current commercial standard which provides higher sensitivity for data acquisition, compared to previous generation 2D scanners.20 However, highly sensitive signal acquisition carries a higher risk for detector saturation which can result in the over-estimation of myocardial blood flow. The saturation effect on dynamic imaging can be prevented by adjusting the injected activity for body weight to optimize the amount of tracer in the bolus first-pass transit.13 To optimize the injected $^{82}$Rb activity in regard to the camera sensitivity, the difference between requested vs injected activity (and volume), maximum vs integral activity, and constant vs variable infusion flow rate are important parameters that need to be taken into consideration. In this context, the current study provides insights to the technical aspects of $^{82}$Sr/$^{82}$Rb generators that can affect the image quality and myocardial blood flow quantification.14 Our results indicated that the RUBY-FILL® elution activity and flow errors (in proportion to the requested values) are exceedingly small, which confirms the high precision of this infusion system. Moody et al. have shown previously that the error in actual measuredrequested dose for the CardioGen-82® generator was up to 50% for a requested activity of 370 MBq (10 mCi) and 33% for a requested activity of 550 MBq (15 mCi), and decreased

| Generator system | Integral (yield) | Maximum (steady-state) |
|------------------|------------------|------------------------|
|                  | GBq (mCi) on first day of use | GBq (mCi) on last day of use | GBq (mCi) on first day of use | GBq (mCi) on last day of use |
| RUBY-FILL®*      | 3.04 ± 0.17      | 0.80 ± 0.01            | 2.31 ± 0.13                  | 0.61 ± 0.01                  |
|                  | (8.22 ± 4.6)     | (21.7 ± 0.1)           | (62.6 ± 3.5)                 | (16.5 ± 0.08)                |
|                  | on day 0         | on day 46              | on day 4                     | on day 56                    |
| CardioGen-82®**  | 3.03 ± 0.21      | 1.07 ± 0.06            | 2.31 ± 0.16                  | 0.81 ± 0.04                  |
|                  | (82.0 ± 5.6)     | (28.9 ± 1.6)           | (62.4 ± 4.3)                 | (22.0 ± 1.2)                 |
|                  | on day 0         | on day 42              | on day 0                     | on day 42                    |

Values are mean ± standard deviation. mCi values = GBq ÷ 27 mCi/GBq
* RUBY-FILL® Maximum values = Integral values ÷ 1.314 correction-factor
**CardioGen-82® Integral values = Maximum values × 1.314 correction-factor
as the requested activity approached 30 mCi (1110 MBq). In our test elutions with RUBY-FILL®, the range of requested elution activity was ~400 to 600 MBq (11 to 16 mCi), and the elution activity error was negligible (less than 0.2%) due to the accurate modeling of eluate transport delay and isotope decay en-route.

*Figure 4.* RUBY-FILL® test elution results (n = 6 each). At each elution flow-rate, the dose-calibrator maximum activity (A) is a constant fraction (slope) of the integrated total QA activity. The corresponding ratios of Dose-calibrator Maximum/Integrated Total calibration activity (B) are extrapolated to the value of 0.761 that would be expected using a 50 mL @ 50 mL·min⁻¹ elution. Standard deviation error bars (~1%) are smaller than the plotted symbol size.
Secondary analysis of the integrated total activity from the RUBY-FILL® test elutions (Supplemental Figure S5) demonstrated similar trends compared to the primary analysis of the dose-calibrator maximum values in Figure 4. The integrated total activity increased consistently as a function of elution flow-rate, up to a peak value 95% of the daily QA calibration activity, using 30 mL at 30 mL-min\(^{-1}\) elution. These data also suggest that if the RUBY-FILL® generator was eluted using the CardioGen-82® protocol (50 mL at 50 mL-min\(^{-1}\)), then the \(^{82}\)Rb yield could increase to \(\sim 120\%\) of the daily QA calibration activity.

Clinical procedure guidelines published by the Society of Nuclear Medicine\textsuperscript{26} recommend that radiopharmaceutical doses should be dispensed and subsequently administered to patients within 10% and 20% of those indicated by the prescribing physician. The U.S. NRC Regulations (10 CFR 35.63) on the use of medical isotopes state “... a licensee may not use a dosage if the dosage does not fall within the prescribed dosage range or if the dosage differs from the prescribed dosage by more than 20 percent”.\textsuperscript{27} The most recent EANM guidelines for PET tumor imaging indicate that for automated administration “actual administered activity may not deviate by more than 3% from that indicated by the device”.\textsuperscript{28} The activity error data from the RUBY-
FILL® generator (Figure S4A) show that this system can meet even these most strict criteria, with actual vs requested activity errors of < 0.11% over all test elutions performed. In comparison, the printed ‘End-of-Infusion’ activity values from the CardioGen-82® breakthrough elution reports appeared to under-estimate the measured dose-calibrator maximum values by ~ 30%, even when using the recommended elution settings of 50 mL at 50 mL-min⁻¹. This underestimation may be due, in part, to the fact that this generator is typically calibrated using a requested ⁸²Rb activity which is less than the total yield available on a given day, and subsequent elutions are only recommended using the same calibration activity.

The accuracy of ⁸²Rb PET dosing is of clinical significance when the imaging results of different PET centers are compared or pooled together as part of multicenter imaging trials. For example, these results may have important implications for the calculation of patient absorbed radiation doses. Effective dose (ED) estimates have been published recently for ⁸²Rb PET in the range of 0.80 and 1.1 mSv-GBq⁻¹ based on PET studies using the RUBY-FILL® and CardioGen-82® generators, respectively. These radiation ED values are calculated using PET image-derived activity values divided (normalized) by the total injected activity, as reported by the respective generator systems. Because of this inverse relationship, higher ED values would be expected from PET studies performed using a generator system which reports lower administered ⁸²Rb activity. In fact, the ratio of ED estimates from the RUBY-FILL®/CardioGen-82® dosimetry papers (0.73) is similar to the CardioGen-82® under-estimation of activity reported in the present study (0.76), providing a possible explanation for the discrepancy between these independently reported ED values. Our results suggest that the lower ED values reported by Hunter et al. using PET studies performed with the RUBY-FILL® system may be more accurate, because the same integrated total activity method of measurement is used both during daily QA calibration and during patient elutions.

**Limitations**

The CardioGen-82® correction-factor was calculated using the RUBY-FILL® daily QA protocol (integrated total activity of 35 mL elution @ 20 mL-min⁻¹) as the reference standard to enable accurate comparison of ⁸²Rb isotope yield and production efficiency between the two systems. The results of this study do not suggest that all generator systems should use the same RUBY-FILL® elution settings above for daily QA, but rather that the dose-calibrator maximum or ‘steady-state’ value measured in a calibration vial consistently under-estimates the integrated total activity delivered to the patient (Figure 2), and that this under-estimation is a function of the elution volume and flow-rate (Figure 4B). The integrated total activity could have been referenced instead to the CardioGen-82® calibration elution settings (50 mL @ 50 mL-min⁻¹) in which case the RUBY-FILL® calibration values would have been multiplied by the extrapolated value of 0.761 for inter-comparison, as shown in Table 2.

Direct comparison of the activity profiles using the same elution flow-rate on both systems was not feasible in this study. The RUBY-FILL® maximum flow-rate is 30 mL-min⁻¹, whereas CardioGen-82® uses a constant 50 mL-min⁻¹ elution flow-rate. The CardioGen-82® system does include a switch to use lower flow-rates (20 or 35 mL-min⁻¹), but these are not part of the approved clinical labeling. Therefore, direct comparison could be performed in future studies if CardioGen-82® daily QA was also measured at a flow-rate of 20 mL-min⁻¹. In the current study, extrapolation of the RUBY-FILL® test elution data from 30 to 50 mL-min⁻¹ was associated with a certain margin of error in estimation of the CardioGen-82® correction-factor. Although the logarithmic and power functions provided excellent fits to these data ($R^2 > 0.98$), the extrapolated values should be interpreted with a degree of caution.

**CONCLUSIONS**

While both ⁸²Rb generators use a similar physical design to produce and administer the radiotracer, differences in the daily QA methods were shown to impact the measured ⁸²Rb yield and efficiency. These characteristics of ⁸²Sr/⁸²Rb generators are of critical importance for accurate patient dosing, in particular when the myocardial perfusion imaging results from different cardiac PET imaging centers are compared or combined for multicenter clinical trials.

**NEW KNOWLEDGE GAINED**

The RUBY-FILL® generator appears to have slightly higher ⁸²Rb isotope production efficiency compared to CardioGen-82®, as well as a longer shelf-life and small elution activity error.

**Disclosures**

AA was supported by a MITACS Elevate fellowship. RSB has received research grants and honoraria from Lantheus Medical Imaging, GE Healthcare and Jubilant DraxImage. RdK and RK receive royalty revenues from rubidium-82 generator technologies, FlowQuant software licenses, and are consultants for Jubilant DraxImage. HCL is a consultant for Jubilant DraxImage.
Open Access

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Ziadi MC. Myocardial flow reserve (MFR) with positron emission tomography (PET)/computed tomography (CT): clinical impact in diagnosis and prognosis. Cardiovascular diagnosis and therapy. 2017;7:206–18.

2. Dorbala S, Di Carli MF, Beanlands RS, Merhige ME, Williams BA, Veledar E, et al. Prognostic value of stress myocardial perfusion positron emission tomography: results from a multicenter observational registry. J Am Coll Cardiol. 2013;61:176–84.

3. Hunter CR, Hill J, Ziadi MC, Beanlands RS, deKemp RA. Biodistribution and radiation dosimetry of (82)Rb at rest and during peak pharmacological stress in patients referred for myocardial perfusion imaging. Eur J Nucl Med Mol Imaging. 2015;42:1032–42.

4. Senthilmzhelvan S, Bravo PE, Esaias C, Lodge MA, Merrill J, Hobbs RF, et al. Human biodistribution and radiation dosimetry of 82Rb. J Nucl Med. 2010;51:1592–9.

5. McCutchan EA. Nuclear Decay Data in the MIRD format. https://www.nndc.bnl.gov/nird Accessed 6 Dec 2019.

6. Klein R, Adler A, Beanlands RS, Dekemp RA. Precision-controlled elution of a 82Sr/82Rb generator for cardiac perfusion imaging with positron emission tomography. Phys Med Biol. 2007;52:659–73.

7. Bushberg JT. The Essential Physics of Medical Imaging. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2011. p. 606–7.

8. Yano Y. Essentials of a rubidium-82 generator for nuclear medicine. Int J Radiat Appl Inst Part A. 1987;38:205–11.

9. Drugs at FDA: RUBY-FILL® In: FDAdataset editor. FDA Center for Drug Evaluation and Research. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/202153s000lbl.pdf. 2016.

10. Schindler TH, Valenta I, Schelbert HR. Myocardial blood flow measurement: evaluating coronary pathophysiology and monitoring therapy. In: Zaret BL, Beller GA editors. Clinical nuclear cardiology; 2010. p. 606-7.

11. Drugs at FDA: Cardiogen-82® In: FDAdataset editor. FDA Center for Drug Evaluation and Research. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/2019414s041lbl.pdf. 2012.

12. Renaud J, Wiles M, Garrard L, R.S. B, dekemp R. New rubidium-82 generator efficiency improves over time. In: SNMMI Annual Meeting. Philadelphia, Pennsylvania; 2018. p. 1045.

13. Renaud JM, Yip K, Guimond J, Trottiier M, Piobarot P, Turcotte E, et al. Characterization of 3-dimensional PET systems for accurate quantification of myocardial blood flow. J Nucl Med. 2017;58:103–9.

14. Klein R, Oceanau A, Renaud JM, Ziadi MC, Beanlands RSB, deKemp RA. Consistent tracer administration profile improves test-retest repeatability of myocardial blood flow quantification with (82)Rb dynamic PET imaging. J Nucl Cardiol. 2018;25:929–41.

15. Klein R, Beanlands RS, deKemp RA. Quantification of myocardial blood flow and flow reserve: Technical aspects. J Nucl Cardiol. 2010;17:555–70.

16. Renaud JM, Wu KY, Gardner K, Aung M, Beanlands RSB, deKemp RA. Saline-push improves rubidium-82 PET image quality. J Nucl Cardiol. 2018.

17. Dorbala S, Di Carli MF. Cardiac PET perfusion: prognosis, risk stratification, and clinical management. Sem Nucl Med. 2014;44:344–57.

18. Dorbala S, Hachamovitch R, Curillova Z, Thomas D, Vangala D, Kwong RY, et al. Incremental prognostic value of gated Rb-82 positron emission tomography myocardial perfusion imaging over clinical variables and rest LVEF. JACC Cardiovasc Imaging. 2009;2:846–54.

19. Ziadi MC, Dekemp RA, Williams KA, Guo A, Chow BJ, Renaud JM, et al. Impaired myocardial flow reserve on rubidium-82 positron emission tomography imaging predicts adverse outcomes in patients assessed for myocardial ischemia. J Am Coll Cardiol. 2011;58:740–8.

20. Yoshinaga K, Klein R, Tamaki N. Generator-produced rubidium-82 positron emission tomography myocardial perfusion imaging: From basic aspects to clinical applications. J Cardiol. 2010;55:163–73.

21. Chatal JF, Rouzet F, Haddad C, Bourdeau C, Mathieu C, Le Guludec D. Story of Rubidium-82 and Advantages for Myocardial Perfusion PET Imaging. Front Med. 2015;2:65.

22. Huizing ED, van Dijk JD, van Dalen JA, Timmer JR, Arkies H, Slump CH, et al. Minimizing rubidium-82 tracer activity for relative PET myocardial perfusion imaging. Nucl Med Commun. 2017;38:708–14.

23. Roby AE, Johnson NP, Gould KL. An analysis of 3 common CardioGen-82 82Rb infusion system injection methods and their impact on clinical volume and image counts. J Nucl Med Technol. 2015;43:113–6.

24. Renaud JM, Mylonas I, McAdrle B, Dowlesy T, Yip K, Turcotte E, et al. Clinical interpretation standards and quality assurance for the multicenter PET/CT trial rubidium-ARMI. J Nucl Med. 2014;55:58–64.

25. Moody JB, Hiller KM, Lee BC, Corbett JR, Ficaro EP, Murthy VL. Limitations of Rubidium-82 weight-adjusted dosing accuracy at low doses. J Nucl Cardiol. 2017;24:1395–401.

26. Callahan RJ, Chilton HM, Ponto JA, Swanson DP, Royal HD, Bruce AD. Procedure guideline for the use of radiopharmaceuticals 4.0. J Nucl Med Technol 2007;35:272-5.

27. United States Nuclear Regulatory Commission: § 35.63 Determination of dosages of unsealed byproduct material for medical use: https://www.nrc.gov/reading-rm/doc-collections/cfr/part035/par t035-0063.html. Last Reviewed/Updated August 29, 2017.

28. Boellaard R, Delgado-Bolton R, Oyen WJ, Giammarile F, Tatsch K, Eschner W et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging 2015;42:328-54.

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.